Article
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Journal for immunotherapy of cancer - 1 Mar 2021
Cao Xu, Li Bolei, Chen Jing, Dang Jessica, Chen Siqi, Gunes E Gulsen, Xu Bo, Tian Lei, Muend Sabina, Raoof Mustafa, Querfeld Christiane, Yu Jianhua, Rosen Steven T, Wang Yingyu, Feng Mingye
Abstract excerpt
BACKGROUND: Limited therapeutic options are available for triple-negative breast cancer (TNBC), emphasizing an urgent need for more effective treatment approaches. The development of strategies by targeting tumor-associated macrophages (TAMs) to stimulate their ability of Programmed Cell Removal (PrCR) provides a promising new immunotherapy for TNBC treatment. METHODS: CD47 is a critical self-protective "don't...
Topics
- Animals
- Antineoplastic Agents, Immunological
- Antineoplastic Combined Chemotherapy Protocols
- CD47 Antigen
- Cell Line, Tumor
- Databases, Genetic
- Drug Synergism
- Female
- Humans
- Macrophage Activation
